Form 4: NovaBay CEO Kazley's Indirect Preferred Stock Acquisition

NovaBay Pharmaceuticals CEO Michael Kazley indirectly acquired convertible preferred stock through R01 Entities, potentially increasing common stock holdings.

Summary

• Michael Kazley, CEO, Director, and 10% Owner of NovaBay Pharmaceuticals, Inc. (NBY), reported an indirect acquisition of convertible preferred stock.
• R01 Fund LP (an 'R01 Entity') purchased 220,663 shares of Series D Non-Voting Convertible Preferred Stock and the rights to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock from David Lazar on October 9, 2025.
• Each share of Series D Preferred Stock will automatically convert into 160 shares of common stock, totaling 35,306,080 common shares, following stockholder approval of Proposal 5 at the annual meeting on October 16, 2025.
• Each share of Series E Preferred Stock will automatically convert into 160 shares of common stock, totaling 21,500,000 common shares, following stockholder approval of Proposal 9 at the annual meeting on October 16, 2025.
• The total potential common stock equivalent from these preferred shares is 56,806,080 shares.
• The reported securities are deemed beneficially owned by R01 Entities, including R01 Capital LLC, R01 Capital Manager LLC, and Michael Kazley, who is the managing member of R01 Capital Manager.
• The R01 Entities disclaim beneficial ownership of these shares, except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The indirect acquisition of a substantial amount of convertible preferred stock by entities associated with the CEO and 10% owner, Michael Kazley, indicates potential long-term commitment and confidence. However, the indirect nature, the beneficial ownership disclaimer, and the contingency on stockholder approval temper the immediate positive sentiment.

Positives

• Indirect acquisition of a significant stake by entities associated with the CEO and a 10% owner, Michael Kazley, may signal confidence in the company's future prospects.
• The transaction consolidates a substantial block of convertible preferred stock under the R01 Entities, potentially streamlining future corporate actions related to these shares.

Negatives

• The acquisition is indirect, through R01 Entities, rather than a direct personal investment by Michael Kazley, which might be perceived differently by some investors.
• Beneficial ownership is disclaimed by the R01 Entities except to the extent of pecuniary interest, adding a layer of complexity to the ownership structure.

Risks

• Conversion of the Series D and Series E Preferred Stock into common stock is contingent upon stockholder approvals of specific proposals (5 and 9) at the annual meeting.
• The conversion of a large number of preferred shares into common stock (56,806,080 shares) could lead to significant dilution for existing common stockholders.
• The complex ownership structure involving R01 Entities and the disclaimer of beneficial ownership could create ambiguity regarding ultimate control and influence.

Future Outlook

The future outlook involves the conversion of Series D and Series E Non-Voting Convertible Preferred Stock into common stock, contingent upon stockholder approvals of proposals 5 and 9 at the annual meeting on October 16, 2025. The Series D Preferred Stock will convert within three business days of the meeting, and the Series E Preferred Stock will convert within thirty business days of the meeting.

Management Comments

• The reported securities may also be deemed to be beneficially owned by R01 Capital LLC, R01 Capital Manager LLC, and Michael Kazley, each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

Industry Context

This Form 4 filing details an insider transaction involving convertible preferred stock, which is a common mechanism for strategic investments and changes in beneficial ownership within publicly traded companies. While the filing itself does not provide specific industry trends, such transactions in the pharmaceutical sector can reflect insider confidence or strategic positioning in a company's long-term prospects.

Comparison to Industry Standards

• The acquisition of convertible preferred stock by an insider group is a standard financial instrument used for strategic investments, similar to practices seen in other growth-oriented sectors where investors seek upside potential with certain protective features.
• The conversion ratio of 160 common shares per preferred share is specific to NovaBay's capital structure and cannot be directly compared without detailed knowledge of other companies' preferred stock terms.
• The use of a Rule 10b5-1 plan (implied by the checkbox) is a common practice for insiders to pre-arrange stock transactions to avoid accusations of trading on material non-public information, aligning with corporate governance best practices.

Corporate Governance

Related Party Transactions

• The transaction involves R01 Fund LP purchasing securities, and Michael Kazley is the managing member of R01 Capital Manager, which is the investment manager for R01 Capital, the general partner of R01 LP. This establishes a related-party transaction between the reporting person's associated entities and the acquisition of company securities.

Stakeholder Impact

• Shareholders: Potential for significant dilution of existing common stock upon conversion of the preferred shares, but also a signal of insider confidence.
• Management: Michael Kazley, through R01 Entities, increases his indirect influence and potential economic interest in the company.
• Creditors: No direct impact on creditors is immediately apparent from this transaction, as it primarily affects equity structure.

Next Steps

• Stockholder approvals of proposals 5 and 9 at the annual meeting on October 16, 2025.
• Automatic conversion of Series D Preferred Stock into common stock within three business days following the annual meeting.
• Automatic conversion of Series E Preferred Stock into common stock within thirty business days following the annual meeting.

Key Dates

Recommendation

The indirect acquisition of a substantial amount of convertible preferred stock by entities associated with the CEO and 10% owner, Michael Kazley, signals potential confidence in the company's future. However, the indirect nature, the beneficial ownership disclaimer, and the contingent nature of the conversion on future stockholder approvals warrant a 'hold' recommendation, awaiting further clarity on the company's operational performance and the actual conversion of these securities. The potential for significant dilution upon conversion also needs to be carefully considered by investors.

Keywords

NovaBay Pharmaceuticals, NBY, Michael Kazley, Form 4, Insider Transaction, Beneficial Ownership, Convertible Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, R01 Entities, Stockholder Approval, Dilution